Thermo Fisher Scientific wraps up acquisition of Mesa Biotech

Thermo Fisher Scientific announced that it has finalized its acquisition of Mesa Biotech for approximately $550 million in total, obtaining the company’s coronavirus test and diagnostic platform.

Mesa Biotech, the maker of the Accula diagnostic system and a COVID-19 test used on the platform, will receive approximately $450 million in cash and could earn an additional $100 million in milestone payments. The company has also developed flu, respiratory syncytial virus (RSV) and Strep A tests that are run on the system.

“The Accula System complements our existing offerings and immediately provides our clinical customers with more options and flexibility for COVID-19 testing,” said Mark Stevenson, executive vice president and chief operating officer of Thermo Fisher Scientific.

FDA News